Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2025 (Aurinia Pharmaceuticals Press Release) - Jul 31, 2025 - "Net Product Sales: For the three and six months ended June 30, 2025, net product sales of LUPKYNIS, the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis, were $66.6 million and $126.5 million, up 21% and 23%, respectively, from $55.0 million and $103.1 million, respectively, for the same periods of 2024....'We look forward to initiating clinical studies in at least two autoimmune diseases in the second half of this year.'"
New trial • Sales • Immunology • Lupus Nephritis
|